144 related articles for article (PubMed ID: 16911391)
41. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma.
Liozon E; Ouattara B; Loustaud-Ratti V; Vidal E
Scand J Rheumatol; 2007; 36(6):484-6. PubMed ID: 18092275
[No Abstract] [Full Text] [Related]
42. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
Lo Nigro A; Ramonda R; Alaibac M; Modesti V; Punzi L
Eur J Dermatol; 2011; 21(2):263-4. PubMed ID: 21411412
[No Abstract] [Full Text] [Related]
43. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
[TBL] [Abstract][Full Text] [Related]
44. Systemic listeriosis with adalimumab therapy.
Murphy G; Schmidt-Martin D; Hynes BG; Harney S
J Clin Rheumatol; 2009 Oct; 15(7):369-70. PubMed ID: 20009978
[No Abstract] [Full Text] [Related]
45. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
Fleischmann R; Shealy D
Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
[No Abstract] [Full Text] [Related]
46. [New treatments for rheumatoid arthritis].
Girault V; Flipo RM
Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
[No Abstract] [Full Text] [Related]
47. Drug-induced lupus erythematosus in a patient treated with adalumimab.
Spillane AP; Xia Y; Sniezek PJ
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S114-6. PubMed ID: 17434034
[No Abstract] [Full Text] [Related]
48. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
[No Abstract] [Full Text] [Related]
49. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
Hirohata S
Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
[TBL] [Abstract][Full Text] [Related]
50. [Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis].
Tomono K; Hashimoto S
Nihon Rinsho; 2005 Jan; 63 Suppl 1():573-8. PubMed ID: 15799420
[No Abstract] [Full Text] [Related]
51. Adalimumab-associated pulmonary fibrosis reply.
Huggett MT; Armstrong R
Rheumatology (Oxford); 2007 Aug; 46(8):1379-80; author reply 1379. PubMed ID: 17553912
[No Abstract] [Full Text] [Related]
52. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
53. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?
Stichenwirth M; Riedl E; Pehamberger H; Tappeiner G
Arch Dermatol; 2008 Jun; 144(6):817-8. PubMed ID: 18559788
[No Abstract] [Full Text] [Related]
54. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy.
Simms R; Kipgen D; Dahill S; Marshall D; Rodger RS
Am J Kidney Dis; 2008 Mar; 51(3):e11-4. PubMed ID: 18295046
[TBL] [Abstract][Full Text] [Related]
55. Safety of biologic therapies--an update.
Keystone EC
J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
[TBL] [Abstract][Full Text] [Related]
56. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
Gabriel SE
Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
[No Abstract] [Full Text] [Related]
57. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
[TBL] [Abstract][Full Text] [Related]
58. Monoclonal gammopathy of undetermined significance and anti-TNF-alpha treatment.
Smale SW; Lawson TM
Scand J Rheumatol; 2007; 36(5):405-6. PubMed ID: 17963174
[No Abstract] [Full Text] [Related]
59. Certolizumab pegol, a pegylated anti-TNF-α antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis.
Koizumi H; Tokuriki A; Oyama N; Ido H; Sugiura K; Akiyama M; Hasegawa M
J Dermatol; 2017 Jun; 44(6):723-724. PubMed ID: 27599405
[No Abstract] [Full Text] [Related]
60. Biologic agents and alopecia areata.
Katoulis AC; Alevizou A; Bozi E; Georgala S; Mistidou M; Kalogeromitros D; Stavrianeas NG
Dermatology; 2009; 218(2):184-5. PubMed ID: 19018127
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
